Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
2.220
+0.130 (6.22%)
At close: Aug 13, 2025, 4:00 PM
2.260
+0.040 (1.80%)
After-hours: Aug 13, 2025, 5:41 PM EDT
Scienture Holdings Revenue
Scienture Holdings had revenue of $128.20K in the twelve months ending June 30, 2025, down -630.13% year-over-year. In the year 2024, Scienture Holdings had annual revenue of $136.64K, down -89.98%.
Revenue (ttm)
$128.20K
Revenue Growth
-630.13%
P/S Ratio
141.55
Revenue / Employee
$6,747
Employees
19
Market Cap
35.49M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
Dec 31, 2022 | 300.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 11 hours ago - SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones. - GlobeNewsWire
- 20 days ago - Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding - GlobeNewsWire
- 4 weeks ago - Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 2 months ago - Scienture Holdings Announces Cancelation of ELOC - GlobeNewsWire
- 2 months ago - Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value - Accesswire
- 2 months ago - SCIENTURE Announces Executive Leadership Transition - GlobeNewsWire
- 3 months ago - SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - GlobeNewsWire
- 4 months ago - SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - GlobeNewsWire